Literature DB >> 20819569

Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin.

Fen Lu1, Xu Li, Ai-Qin Suo, Jie-Wen Zhang.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia in the elderly. The two hallmark lesions in AD brain are deposition of amyloid plaques and neurofibrillary tangles (NFTs). Hypercholesteremia is one of the risk factors of AD. But its role in the pathogenesis of AD is largely unknown. The aim of this study was to investigate the relationship between hypercholesteremia and tau phosphorylation or beta-amyloid (Abeta), and evaluate the effect of atorvastatin on the level of tau phosphorylation and Abeta in the brains of rats fed with high cholesterol diet.
METHODS: Sprague-Dawley (SD) rats were randomly divided into normal diet control group, high cholesterol diet group, and high cholesterol diet plus atorvastatin (Lipitor, 15 mg x kg(-1) x d(-1)) treated group. Blood from caudal vein was collected to measure total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and high-density lipoprotein (HDL) at the end of the 3rd and the 6th months by an enzymatic method. The animals were sacrificed 6 months later and brains were removed. All left brain hemispheres were fixed for immunohistochemistry. Hippocampus and cerebral cortex were separated from right hemispheres and homogenized separately. Tau phosphorylation and Abeta in the brain tissue were determined by Western blotting (using antibodies PHF-1 and Tau-1) and anti-Abeta40/anti-Abeta42, respectively.
RESULTS: We found that high cholesterol diet led to hypercholesteremia of rats as well as hyperphosphorylation of tau and increased Abeta level in the brains. Treatment of the high cholesterol diet fed rats with atorvastatin prevented the changes of both tau phosphorylation and Abeta level induced by high cholesterol diet.
CONCLUSIONS: Hypercholesteremia could induce tau hyperphosphorylation and Abeta production in rat brain. Atorvastatin could inhibit tau hyperphosphorylation and decrease Abeta generation. It may play a protective role in the patho-process of hypercholesteremia-induced neurodegeneration in the brain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819569

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  11 in total

Review 1.  The "aged garlic extract:" (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD).

Authors:  B Ray; N B Chauhan; D K Lahiri
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage.

Authors:  Hai-juan Sui; Ling-ling Zhang; Zhou Liu; Ying Jin
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

3.  Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms.

Authors:  Marcus O W Grimm; Johanna Kuchenbecker; Sven Grösgen; Verena K Burg; Benjamin Hundsdörfer; Tatjana L Rothhaar; Petra Friess; Martijn C de Wilde; Laus M Broersen; Botond Penke; Mária Péter; László Vígh; Heike S Grimm; Tobias Hartmann
Journal:  J Biol Chem       Date:  2011-02-15       Impact factor: 5.157

Review 4.  The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin.

Authors:  Douglas G Peters; James R Connor; Mark D Meadowcroft
Journal:  Neurobiol Dis       Date:  2015-08-22       Impact factor: 5.996

5.  Atorvastatin ameliorates cognitive impairment, Aβ1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.

Authors:  Dongsheng Zhou; Huaxia Liu; Chenli Li; Fangyan Wang; Yaosheng Shi; Lingjiang Liu; Xin Zhao; Aiming Liu; Junfang Zhang; Chuang Wang; Zhongming Chen
Journal:  Metab Brain Dis       Date:  2016-02-16       Impact factor: 3.584

6.  Age, vascular health, and Alzheimer disease biomarkers in an elderly sample.

Authors:  Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Val J Lowe; Jonathan Graff-Radford; Rosebud O Roberts; Michelle M Mielke; Mary M Machulda; Ronald C Petersen; Clifford R Jack
Journal:  Ann Neurol       Date:  2017-10-26       Impact factor: 10.422

7.  Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.

Authors:  Ge Li; Cynthia L Mayer; Daniel Morelli; Steven P Millard; Wendy H Raskind; Eric C Petrie; Monique Cherrier; Anne M Fagan; Murray A Raskind; Elaine R Peskind
Journal:  Neurology       Date:  2017-08-18       Impact factor: 9.910

Review 8.  Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors.

Authors:  Mitsuru Shinohara; Naoyuki Sato; Munehisa Shimamura; Hitomi Kurinami; Toshimitsu Hamasaki; Amarnath Chatterjee; Hiromi Rakugi; Ryuichi Morishita
Journal:  Front Aging Neurosci       Date:  2014-04-23       Impact factor: 5.750

9.  Cholesterol: its regulation and role in central nervous system disorders.

Authors:  Matthias Orth; Stefano Bellosta
Journal:  Cholesterol       Date:  2012-10-17

Review 10.  The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease.

Authors:  Naoyuki Sato; Ryuichi Morishita
Journal:  Front Aging Neurosci       Date:  2015-10-23       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.